May Health Secures $10M Series A to Revolutionize PCOS Treatment

May Health, formerly AblaCare, is thrilled to announce a significant milestone in our ongoing mission to revolutionize the approach to PCOS with our modern, patient-centered solutions. We have successfully raised $10,000,000 in our latest funding round—a robust testament to the confidence investors have in our innovative vision and dedicated team. This capital infusion will accelerate the advancement of our cutting-edge platform, enabling us to expand our research efforts, enhance our technological infrastructure, and deepen our commitment to providing comprehensive care for individuals grappling with PCOS. By infusing state-of-the-art digital tools and data-driven insights into our approach, May Health aims to empower patients with tailored, actionable treatment options, create dynamic educational resources, and foster a supportive community that is integral to the long-term health of those living with the condition. The funding will also bolster our strategic initiatives designed to bridge gaps in the current PCOS landscape, ensuring that our progressive methodologies reach a broader audience while maintaining affordable accessibility. As we embark on this exciting new chapter, our focus remains unwavering: to redefine the PCOS experience with compassionate, innovative care that meets the evolving needs of our patients. This transformative investment not only underscores our commitment to excellence and breakthrough medical strategies but also marks a pivotal moment in driving forward the future of women's health. We extend our heartfelt gratitude to our investors, partners, and team members who have played an essential role in making this achievement possible, and we look forward to delivering outcomes that redefine expectations in the realm of modern healthcare.